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BACKGROUND: Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical trials
in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy
assessments.
METHODS: Patients with castration-resistant prostate cancer with no previous chemotherapy were enrolled in this study. The patients
received tasquinimod up to 1 year either at fixed doses of 0.5 or 1.0mg per day or at an initial dose of 0.25mg per day that escalated
to 1.0mg per day.
RESULTS: A total of 32 patients were enrolled; 21 patients were maintained for X4 months. The maximum tolerated dose was
determined to be 0.5mg per day; but when using stepwise intra-patient dose escalation, a dose of 1.0mg per day was well tolerated.
The dose-limiting toxicity was sinus tachycardia and asymptomatic elevation in amylase. Common treatment-emergent adverse
events included transient laboratory abnormalities, anaemia, nausea, fatigue, myalgia and pain. A serum prostate-specific antigen (PSA)
decline of X50% was noted in two patients. The median time to PSA progression (425%) was 19 weeks. Only 3 out of 15 patients
(median time on study: 34 weeks) developed new bone lesions.
CONCLUSION: Long-term continuous oral administration of tasquinimod seems to be safe, and the overall efficacy results indicate that
tasquinimod might delay disease progression.
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In developed countries, prostate cancer is the second most
frequently diagnosed cancer, and the third most common cause
of death from cancer in men (Damber and Aus, 2008) with
B240000 new cases and B85000 deaths a year from this cancer in
Europe (Boyle and Ferlay, 2005). Metastatic disease is initially
treated with androgen deprivation, which results in significant
palliation for most patients (Huggins and Hodges, 1941; Denmeade
and Isaacs, 2002). However, despite androgen deprivation and
secondary hormonal manipulations, most patients eventually
relapse on androgen ablative therapy and develop castration-
resistant prostate cancer (CRPC). The median survival for patients
with metastatic CRPC is 12–16 months from the time of diagnosis
to death (Heidenreich and Schrader, 2003). No curative treatments
are available at this stage of the disease. To date, docetaxel-based
regimens have shown a modest survival advantage (Petrylak et al,
2004; Tannock et al, 2004). A lack of cancer cell specificity limits
both dose and total length of treatment with cytotoxic agents.
Thus, there is a high medical need for novel and well-tolerated
agents that delay disease progression.
After neovascularisation was identified as a prerequisite for
growth and metastasis of solid tumours (Folkman, 1972), direct or
indirect inhibition of angiogenesis has become a viable therapeutic
approach in anti-cancer therapy. By the inhibition of tumour
neovascularisation, tumour growth is suppressed. There is a
significant correlation between the density of microvessels and the
incidence of metastases in prostate cancer (Weidner et al, 1993).
These observations make the angiogenic pathway a rationale target
for directing therapies in prostate cancer and an attractive
approach to new treatment options (Figg et al, 2002;
Aragon-Ching and Dahut, 2008).
Tasquinimod (ABR-215050; CAS number: 254964-60-8) is a
quinoline-3-carboxamide derivative inhibiting tumour angiogen-
esis (Isaacs et al, 2006; Dalrymple et al, 2007). Although the anti-
angiogenic mechanism of action of tasquinimod is presently
unknown, it is not a vascular endothelial growth factor receptor
(VEGFR) inhibitor. Pre-clinically, tasquinimod produced a robust
inhibition of prostate cancer growth in vivo in a range of
phenotypes and genotypes most characteristic of clinical tumours
from patients with localised or metastatic, androgen receptor
(AR)-positive or AR-negative, AR wild-type or mutant, as well as
prostate-specific antigen (PSA)-positive or PSA-negative cancers.
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 1 of tasquinimod over
a period of 1 month decreased the tumour volume by at least 50%
(Isaacs et al, 2006). This decrease in tumour volume was associated
with a significant decrease in tumour blood vessel density.
Similarly, the studies documented that a combination of androgen
ablation or docetaxel with tasquinimod produced enhanced
tumour growth retardation above that induced by either agent
alone (Dalrymple et al, 2007).
In this study, we report the results of phase I studies in men with
CRPC and PSA recurrence. The trials were conducted to define the
safety and tolerability of tasquinimod when administered once
daily and to serve as a basis for dose selection in future phase II
studies. In addition, the studies investigated pharmacokinetics and
the preliminary efficacy of tasquinimod.
PATIENTS AND METHODS
Patients
A total of 32 patients were enrolled for two multi-centre studies
between February 2005 and January 2007. Eligibility criteria
included informed consent, histologically or cytologically proven
CRPC with PSA progression that was documented by at least two
consecutive increases in PSA separated by at least 1 week during a
maximum of 12 months before the initiation of therapy and a
castrate level of testosterone (o50ng per 100ml) achieved by
androgen-deprivation therapy through either surgical or pharma-
cological castration. Patients on a LHRH agonist were to continue
androgen suppression during the studies. Patients who had
received previous anti-androgen therapy were to have documented
a subsequent increase in PSA after ceasing the anti-androgen.
Patients were allowed on study without a detectable metastatic
disease as assessed by bone scan or computed tomography (CT),
provided they had documented increases in PSA. Patients had to
have a score of 0 or 1 on the ECOG (Eastern Cooperative Oncology
Group) performance status, and to have adequate bone marrow,
renal and hepatic functions. Patients were excluded if they had
clinical symptoms associated with prostate tumour progression,
had received previous anti-cancer therapy (except for hormonal
treatments), required systemic corticosteroids or warfarin, had
previous significant cardiac events or had uncontrolled inter-
current illness. The use of strong CYP3A4 inhibitors or inducers
was not permitted while on study because of potential drug
interaction. The study was conducted in accordance with the
Declaration of Helsinki, Good Clinical Practice Guidelines, ethical
committee approval and applicable local laws and regulations.
Study design
The first of the two open-label studies conducted, study I, was a
dose-escalation study to determine the maximum tolerated dose
(MTD) of tasquinimod defined as the highest dose level at which
no more than 1 out of 6 patients experienced a dose-limiting
toxicity (DLT). Any drug-related grade 3 or 4 toxicity was
considered a DLT. A cohort of six eligible patients was to receive
an initial dose of 0.5mg orally once daily. If the patients tolerated
this dose level, next cohorts, each comprising six patients, were to
receive escalating doses (1.0, 2.0 and 3.0mg per day) of
tasquinimod until the MTD was determined. The patients were
to receive treatment with tasquinimod for 28 days, followed by a
1-week off period, and during an extension study thereafter for up
to 12 months (Figure 1). Dose escalation would stop if 2 DLTs were
observed within a cohort, and the preceding cohort would be
expanded with an additional 10 patients to allow greater precision
for the estimates of toxicity.
The second study conducted, study II, was an intra-patient
stepwise dose-escalation study in eight patients. The patients were
to receive an initial dose of 0.25mg orally once daily for 3 weeks,
and in the absence of treatment-related toxicity 0.5mg per day for
another 3 weeks and finally 1.0mg per day for an additional 4
weeks. In the absence of treatment-related toxicity, patients were
offered to continue their treatment at 1.0mg per day during an
extension study for another 11 months.
According to study protocols, treatment was discontinued
because of disease progression (investigator’s decision), treat-
ment-related toxicity or withdrawal of consent.
Procedures
In study I, patients were examined on days 1, 5, 8, 15, 23, 28, 35, 49,
63 and every 4 weeks thereafter until the final visit at 13 months.
Safety evaluation was conducted at baseline and at each visit
thereafter; that is, all patients underwent a physical examination,
and vital signs, haematology, clinical chemistry, coagulation,
urinalysis and ECG were evaluated. In addition, serum PSA values
were measured at days 1, 15, 28, 35 and at every 4 weeks thereafter
until the final visit. A PSA response was defined as a decrease in
PSA 450% from the baseline value and was confirmed by a second
PSA value 4 weeks later (Bubley et al, 1999). The time to PSA
progression was defined as the time from randomisation to a
X25% increase in serum PSA from baseline or from on-treatment
nadir PSA value (Scher et al, 2008). The PSA doubling time
(PSADT) was calculated using the log-slope method (Daskivich
et al, 2006). Regression analyses were conducted for the historic
Study I – Fixed dose
Extension phase up to 12 months
1 week off
(0.5, 1, 2 or 3 mg day–1)
Study II – Intra-patient dose escalation
Extension phase up to 11 months
1.0 mg day–1
0.5 mg day–1
0.25 mg day–1
Week 1         2        3        4         5        6        7        8         9       10     11     12
Figure 1 Study design of study I and study II.
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sand on-study PSA data. Historic regression analysis was conducted
using weighted linear regression. More weight was given to
samples, which were closer to the screening visit. The weights were
set at 1, 0.5 and 0.25 for values not older than weeks 16, 32 and 52,
respectively, before the first dose. Values older than week 52 before
screening were excluded. In the on-study regression analysis, the
same weight (weight¼1) was given to all PSA values collected
throughout the study.
Radiological imaging with bone scan was performed at screen-
ing and at every 2 months until the final visit. The overall time to
PSA progression and radiographic progression was defined using
Kaplan–Meier methods.
In study II, patients visited the study site on days 1, 5, 8, 15, 26,
29, 36, 47, 50, 57, 71 and at 3 months and every 2 months thereafter
until the final visit at 12 months. The procedure for safety
evaluation was the same as in study I. PSA measurements were
performed at baseline, on day 71 and every 2 months thereafter.
In study I, extensive pharmacokinetic sampling was performed
on days 1 and 28. Besides, a blood sample (pre-dose) was collected
at all visits. Tasquinimod concentrations in plasma samples were
determined using a validated liquid chromatography mass
spectrometry/mass spectrometry method. Briefly, the plasma
sample was prepared for injection onto the column by protein
precipitation, followed by centrifugation. Quantitation was based
on stable isotope dilution. The workable concentration range for
the method was 1–2500nmoll
 1 with inter-batch precision and
accuracy in the same concentration interval being 6.1 and 102.9%,
respectively. Pharmacokinetic parameters, including area under
the concentration–time curve (AUC), maximum concentration
(Cmax), time to Cmax (tmax) and elimination half-life (t1/2) were
evaluated by non-compartmental analysis using WinNonlin
professional software version 5.0.1 (Pharsight Corp., Mountain
View, CA, USA).
Statistical evaluations
All variables are presented using descriptive statistics. No formal
statistical tests were conducted in these studies.
RESULTS
Patient characteristics
In total, 32 patients were enrolled for these studies. Baseline
clinical and biological characteristics are described in Table 1.
Patients ranged in age from 46 to 82 years, and all of them were
Caucasian. There were no clinically meaningful differences
between the patients in baseline characteristics in the two studies,
including factors with established prognostic importance in
prostate cancer (Smaletz et al, 2002; Armstrong et al, 2007). The
median PSA concentration at study entry was 19ngml
 1 (range:
2.6–1400). Pre-treatment median PSADT was 25 weeks (range: 8 to
4999). Two patients had a decline in PSA just before entering the
study, in one patient after discontinuing anti-androgen treatment.
Bone scan was performed in study I, and 50% of the patients had
bone metastatic disease at baseline.
Efficacy
Two patients in the 0.5mg dose group in study I had a PSA decline
of 450% at 10 and 26 weeks, lasting for 47 and 13 weeks,
respectively. An additional patient had a decline of 430% at 9
weeks lasting for 12 weeks. The best PSA response in all patients
treated for 415 days (n¼28) are graphically shown in the
waterfall chart in Figure 2. The estimated proportion of patients
without PSA progression at week 18 was 56%. The median PSA
progression-free time was 19 weeks (95% CI, 13–25 weeks; n¼23)
in patients entering the extension phase (Figure 3). The median
pre-treatment PSADT was 25 weeks, and the median PSADT at 18
weeks was 65 weeks. In all, 18 patients had prolonged PSADT while
on study; in 5 patients PSADT was shortened.
Bone scans were performed at baseline and thereafter at every 2
months in the fixed 0.5mg dose group. In all, 7 (47%) out of 15
patients continuing during the extension study had positive scans
at baseline. It is noteworthy that there was no finding of bone scan
progression at the end of study in 12 (80%) patients (median
treatment time: 34 weeks; range: 15–54) (Figure 4). One (14%)
patient with a positive scan at baseline developed new lesions at
week 53; two (25%) patients with negative scans at baseline
developed new bone lesions at weeks 13 and 21, respectively. No
patient in the trial developed tumour-related pain requiring
treatment with opioid drugs. The median time to PSA progression
for patients with and without bone lesions at baseline was 9 (95%
CI, 5–23 weeks; n¼7) and 23 weeks (95% CI, 13–56 weeks; n¼8),
Table 1 Baseline characteristics
Study I
a (n¼24)
Variable
0.5mg per day
(n¼17)
1.0mg per day
(n¼7)
Study II
b
(n¼8)
Age, years
Median 72 77 73
Range 46–82 58–82 61–78
PSA, ng per 100ml
Median 19 112 9.4
Range 2.6–1400 6.3–1188 5.0–25
PSADT, weeks
Median 23 27 29
Range 8 to 4999 13–81 9 to 4999
Gleason’s score
Median 7 7 7
Range 6–9 6–10 6–9
Gleason’s score, n
p6 1 (6%) 1 (14%) 1 (13%)
7 6 (35%) 2 (29%) 3 (38%)
8–10 6 (35%) 2 (29%) 2 (25%)
Indeterminate 4 (24%) 2 (29%) 2 (25%)
Bone metastases
c
M0 8 (47%) 4 (57%) 3 (38%)
M1 9 (53%) 3 (43%) 3 (38%)
MX 0 0 2 (25%)
ECOG, n
0 17 (100%) 6 (86%) 7 (88%)
1 0 1 (14%) 0
Indeterminate 0 0 1 (13%)
Haemoglobin, gl
 1
Median 142 127 133
Range 124–154 107–140 126–148
Alkaline phosphatase, mkatl
 1
Median 1.2 1.5 1.6
Range 0.8–10 0.7–3.2 0.9–2.1
Lactate dehydrogenase, mkatl
 1
Median 3.5 3.7 2.9
Range 2.1–5.7 3.1–4.3 2.2–3.5
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; PSA¼prostate-
specific antigen; PSADT¼prostate-specific antigen doubling time.
aFixed dose
groups.
bIntra-patient dose-escalation group.
cNo soft tissue lesions were observed.
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also progressed by PSA criteria.
Notably, patients treated with tasquinimod responded with a
decrease in serum lactate dehydrogenase (LDH) levels. Compared
with baseline, patients had a LDH mean (±s.e.m.) decrease of
20±3% at 4 months.
Maximum tolerated dose
In study I, 24 patients received tasquinimod at fixed doses of 0.5
(17 patients) or 1.0mg (7 patients) orally once daily on a
continuous dosing schedule for 28 days. Patients treated at the
0.5mg dose level tolerated the therapy without DLT. In the cohort
comprising seven patients at a dose level of 1.0mg per day, two
patients experienced DLT as pre-defined by protocol (Table 2).
One patient had an asymptomatic CTC grade 3 elevation in
amylase on day 23. He recovered without any clinical intervention
within 2 weeks. The second DLT patient had chest and back pain
and was hospitalised on day 10 because of a grade 3 cardiac
arrhythmia. The patient had periods of supraventricular tachy-
cardia. There were no signs consistent with myocardial infarction.
He received treatment with b-blockers and recovered 2 weeks later.
Owing to these events, the remaining patients in the 1.0mg dose
group were discontinued prematurely. The MTD of tasquinimod
was determined to be 0.5mg once daily.
The 0.5mg dose group was expanded with an additional 11
patients. All patients in the 0.5mg dose group completed the
28-day treatment period. After 1-week of treatment, patients
without signs of tumour progression were offered to continue
tasquinimod treatment for up to 12 months. In all, 15 (88%) out of
the 17 patients entered the extension phase. The mean number of
days with intake of study drug in the 0.5 and 1.0mg dose groups
was 240 and 11, respectively. Three (20%) patients completed the
12-month extension study.
Safety results
Inflammation (41%) was the most common adverse event
associated with tasquinimod in the fixed 0.5mg dose group during
the first 4 weeks of treatment (Table 3). In this study, inflammation
is defined as increased levels of laboratory markers, constituting
laboratory changes above the upper limit normal not associated
with clinical symptoms requiring any clinical intervention. In the
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Figure 2 Waterfall plot of best PSA response per subject, with each bar
representing one patient’s lowest percentage decline after treatment
initiation (n¼28). The 28 patients are divided into three groups (M0, M1,
and MX) according to distant metastasis on bone scan at baseline.
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Figure 3 Kaplan–Meier graph of time to PSA progression (PSA increase
425% over baseline or on-treatment NADIR) in patients entering the
extension phase (n¼23; censored subjects¼circle). The median PSA PFS
was 19 weeks.
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Figure 4 Kaplan–Meier graph of time to new bone lesions in
patients treated at a fixed dose of 0.5mg per day (n¼15; censored
subjects¼circle).
Table 2 No. of patients with tasquinimod related CTC grade 3 adverse
events/SAE/DLT
Dose level mg
per day
No. of
patients SAE DLT
Study I
Back pain 0.5 1
Hyperamylasaemia 0.5 2
1.0 1 1
Sinus tachycardia 1.0 1 1 1
Study II
Cerebral infarction 1.0 1 1
Chest pain 1.0 1 1
a
Abbreviation: DLT¼dose-limiting toxicity.
aThis patient also experienced another
Serious Adverse Event (SAE), musculoskeletal pain Common Toxicity Criteria (CTC)
grade 2.
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most common adverse events. The majority of these events was
CTC grade 1 in severity, transient and occurred early after the start
of treatment.
The most commonly occurring adverse events assessed as
related to tasquinimod in the intra-patient dose-escalation study
(study II) were myalgia (25%), hypoesthesia (25%) and pain in
extremity (25%).
Compared with baseline, patients in both study I and study II
had mean haemoglobin decreases of 12 and 16gl
 1, respectively.
These changes occurred within 2 weeks of the initiation of
treatment and were stabilised 6 weeks later, except for one case of
anaemia for which a blood transfusion was required.
In the fixed 0.5mg dose group, there were decreases in mean
systolic and diastolic blood pressure levels starting during the first
weeks of treatment continuing throughout the study. At 3 months,
the mean (±s.e.m.) systolic blood pressure was decreased by
20.6±5.3mmHg and the diastolic blood pressure by
5.3±2.4mmHg. At 10 weeks in the intra-patient dose-escalation
study, there was also a similar decrease in mean (±s.e.m.) systolic
and diastolic blood pressure levels, that is, 18.1±6.4 and
7.4±2.0mmHg, respectively. No other changes in vital signs
(mean pulse, mean oral body temperature, mean body weight) or
ECG parameters were considered clinically relevant.
In study I, five patients experiencing severe adverse events (CTC
grade 3) were documented (Table 3). No adverse event of CTC
grade 4 was observed. Two patients in the 0.5mg dose group
developed asymptomatic CTC grade 3 elevations in amylase on
day 8. These abnormalities resolved without treatment interrup-
tion and were normalised within 7 days. A third patient
experienced back pain. He recovered with sequelae in one day.
The two patients who experienced DLT are described above.
In study II, three SAEs were recorded in two patients during the
study in which a causal relationship with tasquinimod could not be
excluded. One patient experienced two SAEs, namely musculoske-
letal pain (CTC grade 2) and chest pain (CTC grade 3). The patient
discontinued the study because of the pain and recovered. Another
patient experienced an SAE of cerebral infarction (CTC grade 3).
Approximately 1 year after starting to take the study drug, this
patient noted aphasia and poor coordination of his left body half
and was hospitalised. A CT scan of the brain showed no
pathological changes. He received treatment with enalapril,
acetylsalicylic acid and simvastain. The patient recovered and
was discharged from the hospital 3 days later.
Table 3 Percentage of patients with tasquinimod-related adverse events (only symptoms occurring in two or more patients (n¼32))
Fixed 0.5mg per
day (n¼17)
Fixed 1.0mg
per day (n¼7)
Fixed 0.5mg per day
extension (n¼15)
0.25–1.0mg
per day (n¼8)
SOC
Dictionary-
derived term
Grades
1 and 2 (%)
Grade
3( % )
Grades
1 and 2 (%)
Grade
3( % )
Grades
1 and 2 (%)
Grade
3( % )
Grades
1 and 2 (%)
Grade
3( % )
Blood and lymphatic system
disorders
Anaemia 18 29 33
Gastrointestinal disorders Abdominal pain 12
Constipation 12 7 13
Nausea 6 57 13
General disorders and
administration site conditions
Fatigue 18 43 7 13
Feeling cold 6 29
Inflammation 41 29 33
Pain 12
Pyrexia 6 13
Investigations Blood fibrinogen
increased
24 7
CRP increased 24
Hb decreased 6 7
Monocyte count
increased
12 7
Neutrophil count
increased
12 7
Platelet count
increased
61 3
ESR increased 18 7
WBC count
increased
24 7
Metabolism and nutrition
disorders
Hyperamylasaemia 12 14 7
Hypercalcaemia 6 14
Musculoskeletal and connective
tissue disorders
Arthralgia 14 13
Muscular weakness 6 7
Musculoskeletal
stiffness
61 4
Myalgia 18 7 25
Pain in extremity 6 25
Nervous system disorders Headache 6 7 13
Hypoesthesia 25
Psychiatric disorders Insomnia 6 7
Skin and subcutaneous tissue
disorders
Eczema 6 7
Abbreviations: Hb¼haemoglobin; WBC¼white blood cell; CRP¼C-reactive protein; ESR¼erythrocyte sedimentation rate; SOC¼system organ class.
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In the 0.5mg fixed dose group, the maximum plasma concentra-
tion (Cmax) (mean: 0.26mmoll
 1, n¼17), was attained at 2.6h. The
oral clearance (CL/F) was 0.28lh
 1 (mean) and the oral volume of
distribution (V/F) was 15l (mean), resulting in an elimination half-
life of 40±16h (mean±s.d.). The AUC at steady state amounted to
4.8mmolhl
 1 (mean). The accumulation ratio in plasma level
(AUC24h) by multiple dosing was 2.8 and was expected on the basis
of the half-life of tasquinimod. The steady-state plasma concentra-
tions of tasquinimod showed no time dependency in the exposure
during up to 1 year of treatment: the state pre-dose (trough)
concentration of tasquinimod (mean: 0.19mmoll
 1) determined
during 12 months of daily administration was the same as after 14
days of administration. The pharmacokinetic properties were not
affected by food intake. The pre-dose plasma concentrations of
tasquinimod determined after 14 days of daily administration at
0.25, 0.5 and 1.0mg in the intra-patient dose-escalation study were
0.13±0.02, 0.23±0.03 and 0.42±0.05mmoll
 1 (mean±s.e.m.,
n¼8), respectively. No essential dose dependency of the
pharmacokinetics was observed.
DISCUSSION
Structurally, tasquinimod is related to roquinimex (linomide),
which was tested in a series of phase II and III trials in patients
with advanced renal cell carcinoma (de Wit et al, 1997; Pawinski
et al, 1997) and in those with multiple sclerosis (MS) (Noseworthy
et al, 2000). In patients with renal cell cancer, the efficacy was
modest with influenza-like symptoms of myalgia, arthralgia and
fatigue being the most common adverse events. Roquinimex was
terminated because of unanticipated serious cardiopulmonary
toxicities detected in studies on MS patients. The mechanism of
these adverse effects is unknown, but may be related to a
proinflammatory reaction seen in a polyarthritis model mimicking
proinflammatory side effects in the dog. Doses of roquinimex that
inhibit tumour growth in the mouse induce a proinflammatory
reaction in the dog. Its main characteristics are fever, neutrophilia
and an increase in acute-phase reactant levels (Jo ¨nsson et al, 2004).
When the toxicity of tasquinimod was assessed in dogs, only
occasional increases in acute-phase reactants and white blood cell
counts were observed (unpublished observation), and hence
inducing systemic inflammatory reactions seems to have less
significance for tasquinimod. Pre-clinically, tasquinimod is 30–60
times more potent than roquinimex in its anti-tumour efficacy
(Isaacs et al, 2006). Thus, compared with roquinimex, significant
improvements in both anti-angiogenic and anti-prostate cancer
activities and safety aspects have been accomplished in tasquini-
mod.
On the basis of the effects of tasquinimod against human
prostate cancer xenografts, it has entered clinical development
as therapy for prostate cancer. These phase I trials were conducted
to evaluate the safety and preliminary efficacy of tasquinimod in
men with asymptomatic CRPC without previous systemic che-
motherapy.
In these phase I studies, tasquinimod could be safely
administered at 0.5–1.0mg per day during long-term
treatment. Most adverse events occurred within the first 4 weeks
of treatment. Of a total of 71 related adverse events in the fixed
0.5mg dose group, 76% were recorded until day 35. Raised
inflammatory markers not associated with clinical symptoms are
the most frequent adverse effects, whereas fatigue, myalgia and
nausea are the most common symptomatic adverse events. Nausea
seemed to be related to taking tasquinimod under fasting
conditions.
On the basis of the observations that most laboratory changes
were transient, not associated with clinical symptoms and occurred
early after the start of treatment, an intra-patient stepwise dose-
escalation study was conducted to determine whether these
laboratory changes could be reduced. Given the small sample
size in the intra-patient dose-escalation group, it is not possible to
provide a precise estimate, but the intra-patient dose-escalation
regimen seemed to decrease the number of related adverse
events per patient per month. Thus, the intra-patient dose-
escalation regimen may prove beneficial to future trials with
tasquinimod.
Several patients developed asymptomatic elevations in
amylase B1 week after the start of treatment. Amylase levels
normalised without dose interruption within a couple of weeks.
The reasons for this transient elevation in amylase are unknown.
As hyperamylasaemia was not associated with clinical symptoms
and no patient developed acute pancreatitis, it is possible that the
asymptomatic increase in amylase should not be considered as a
relevant DLT. Notably, asymptomatic increases in serum
levels of amylase and lipase have been observed with the anti-
angiogenic agents such as sorafenib, sunitinib, and temsirolimus
and may represent a class effect (Escudier et al, 2006; Bhojani et al,
2008). However, other side effects noted with VEGFR inhibitors
and agents targeting VEGF such as skin rashes, hand–foot skin
reactions, diarrhoea, hypertension and neuropathic changes
(Kane et al, 2006; Rock et al, 2007) were not observed with
tasquinimod. Thus, there seems to be a substantial difference in
the side effect profile of tasquinimod compared with VEGFR
inhibitors.
Several anti-angiogenic therapies are currently under intense
clinical investigation both as stand-alone therapies and as
adjuvants to chemotherapy to enhance the anti-tumour activity
of the latter. In general, the PSA response of the anti-angiogenic
agents as stand-alone therapies in metastatic androgen-indepen-
dent prostate cancer is modest (Figg et al, 2001; Reese et al, 2001;
Steinbild et al, 2007; Dahut et al, 2008).
The present trials were primarily designed to evaluate the
safety of tasquinimod. However, efficacy was addressed by
measuring PSA levels in all patients and by bone scan in
patients treated at 0.5mg per day. Preclinical data suggest that
the effect of tasquinimod on serum PSA levels is related to its
inhibitory effect on tumour growth (Dalrymple et al, 2007), which
supports a hypothesis that a clinical change in PSA slope or
PSADT is indicative of a therapeutic response to tasquinimod. In
the current studies, 56% of patients were progression free by PSA
criteria (o25% increase) at 18 weeks. The median PSADT up to 18
weeks was 65 weeks compared with the median pre-treatment
PSADT of 25 weeks. In this respect, tasquinimod as a stand-alone
therapy seems to be superior to most other anti-angiogenic
agents both in terms of PSA progression-free survival and PSA
declines. Repeated radiological imaging with bone scan was
performed in patients who received the fixed dose of 0.5mg per
day. Seven of these patients had a positive bone scan at baseline,
whereas eight patients had negative scans. Only three (20%)
patients had radiographic progression on bone scans. Two of
these patients had negative bone scans at baseline. No patient had
evidence of tumour-related pain. However, this study did not
conform to the recent recommendation of the PCWG2
(Prostate Cancer Clinical Trials Working Group) to assess the
progression on bone scan (Scher et al, 2008). Therefore, it is
important that future studies be harmonised with these novel
recommendations. Two patients had PSA progression (at 5 and 9
weeks, respectively) before radiographic progression (at 53 and 13
weeks, respectively), and one patient had PSA and radiographic
progression at the same time (at 21 weeks). Two of these patients
had negative bone scans at baseline. No patient had evidence of
tumour-related pain.
Lactate dehydrogenase levels may be a marker for tumour
burden (Smaletz et al, 2002; George et al, 2005). It was observed
that patients experienced a decrease in their LDH levels during
treatment. Interestingly, LDH levels are not affected in healthy
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phosphatase levels were only affected to a minor extent.
In conclusion, there is a need for novel therapies for treating
metastatic prostate cancer. Anti-angiogenic therapy has demon-
strated its potential as a therapy to stabilise or delay disease
progression. Although caution must be exercised in interpreting
early data, treatment in the form of long-term continuous oral
administration of tasquinimod seems to be safe and well tolerated
with a favourable pharmacokinetic profile, and overall efficacy
results indicate that tasquinimod might delay disease progression.
On the basis of the encouraging phase I results, a randomised
phase II program is currently being performed to further
determine the efficacy and safety of tasquinimod in asymptomatic
patients with metastatic CRPC. The tasquinimod profile demon-
strated may also prove beneficial to future trials combining
tasquinimod with chemotherapy, radiation, anti-hormonal or
other anti-angiogenic agents.
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